IPG Photonics (IPGP) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
12 Feb, 2026Executive summary
Fourth quarter revenue rose 17% year-over-year to $274.5 million, driven by strong growth in materials processing, medical, and advanced applications, with stable industrial demand and new business in battery production.
Net income for the quarter was $13.3 million, up 71% year-over-year; adjusted EBITDA reached $41.2 million, an 11% increase year-over-year, and adjusted EPS was $0.46, up 53%.
Strategic focus on high-value applications and innovation led to record medical sales, successful integration of cleanLASER, and the launch of new products.
Book-to-bill ratio above one in Q4 signals improving market conditions and strengthening demand.
Full-year revenue grew 3% to $1,003.8 million, marking the first annual growth since 2021.
Financial highlights
Q4 revenue reached $274.5 million, up 17% year-over-year and 9% sequentially; foreign currency contributed $6 million.
GAAP gross margin was 36.1%, down from 38.6% a year ago, impacted by tariffs and higher product costs; adjusted gross margin was 37.6%.
GAAP operating income was $3 million; adjusted EBITDA $41.2 million; GAAP net income $13.3 million ($0.31 per share); adjusted net income $20 million ($0.46 per share).
Operating expenses increased 21% year-over-year, mainly due to growth investments and acquisition-related costs.
Ended the quarter with $839 million in cash and no debt; full-year free cash flow was $75 million.
Outlook and guidance
Q1 2026 revenue expected between $235 million and $265 million, with seasonality impacting results.
Adjusted gross margin guidance of 37%-39%, with tariffs expected to impact margins by 150 basis points.
Adjusted EPS forecasted at $0.10-$0.40; adjusted EBITDA $25-$40 million.
CapEx for 2026 projected at $90-$100 million, reflecting delayed investment in Germany.
Operating expenses for Q1 2026 projected at $90–$92 million.
Latest events from IPG Photonics
- Q2 2026 revenue up 11% with strong industrial demand, margin gains, and Lumibird Medical deal.IPGP
Q2 20264 Aug 2026 - €300M acquisition expands medical laser leadership, adds $1B market, and targets Q4 2026 close.IPGP
M&A announcement17 Jul 2026 - Q3 revenue declined 23% and net loss reached $233.6M, but adjusted EPS was $0.29.IPGP
Q3 20248 Jul 2026 - Q1 revenue beat guidance despite a 10% drop, with strong bookings and tariff-related Q2 risks.IPGP
Q1 20258 Jul 2026 - Revenue up 17% year-over-year, led by Industrial Solutions, but net income declined on higher costs.IPGP
Q1 20265 May 2026 - Growth, compensation realignment, and board-backed proposals mark a transformative year.IPGP
Proxy filing5 May 2026 - 2025 saw revenue growth, strong governance, performance-based pay, and expanded ESG oversight.IPGP
Proxy filing1 Apr 2026 - Votes will be cast on directors, executive pay, and auditor ratification at the May 2026 meeting.IPGP
Proxy filing1 Apr 2026 - Growth driven by innovation, new markets, and strong financials positions the business for expansion.IPGP
47th Annual Raymond James Institutional Investor Conference2 Mar 2026